Table 2. Tumor recurrence rates in patients with HR+ DCIS after mastectomy.
Table 2—source data 1. Tumor recurrences in patients with hormone receptor positive (HR+) ductal carcinoma in situ (DCIS) after mastectomy.
elife-83045-table2-data1.xlsx (40.6KB, xlsx)
| Tumor recurrence | ET (N=19) | Non-ET (N=4) |
|---|---|---|
| Invasive local recurrence | 4 (21%) | 0 (0%) |
| Contralateral breast cancer | 3 (16%) | 0 (0%) |
| Distant metastasis | ||
| Bone | 6 (32%) | 1 (25%) |
| Liver | 2 (11%) | 2 (50%) |
| Lung | 1 (5%) | 0 (0%) |
| Brain | 1 (5%) | 0 (0%) |
| Abdominal cavity | 1 (5%) | 1 (25%) |
| Lymph nodes | 1 (5%) | 0 (0%) |
Notes: Data are n (%). HR, hormone receptor; DCIS, ductal carcinoma in situ; ET, endocrine therapy.
Source files available in Table 2—source data 1.